Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice.
Investors KidneyIntelX

Management Change

LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “ Ordinary Shares ”) (the “


Read More
By |2024-04-18T17:17:12+00:0004.18.24|News|Comments Off on Management Change

Renalytix Announces Financing with Expected Size of up to $4 Million

LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “ Ordinary Shares ”) (the “


Read More
By |2024-04-23T20:56:19+00:0004.08.24|News|Comments Off on Renalytix Announces Financing with Expected Size of up to $4 Million

KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)

Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final


Read More
By |2024-04-23T20:56:20+00:0003.14.24|News|Comments Off on KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second


Read More
By |2024-04-23T20:56:20+00:0002.15.24|News|Comments Off on Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second

Read More
By |2024-02-15T07:01:00+00:0002.15.24|News|Comments Off on Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease

Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months Results demonstrated a 61% increase in preventative drug prescriptions among patients in the high-risk


Read More
By |2024-04-23T20:56:21+00:0001.10.24|News|Comments Off on New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today


Read More
By |2024-04-23T20:56:22+00:0011.14.23|News|Comments Off on Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14

LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live


Read More
By |2024-04-23T20:56:22+00:0011.07.23|News|Comments Off on Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and


Read More
By |2024-04-23T20:56:23+00:0010.06.23|News|Comments Off on US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

Renalytix Reports Full Year Fiscal 2023 Results

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care,


Read More
By |2024-04-23T20:56:23+00:0009.28.23|News|Comments Off on Renalytix Reports Full Year Fiscal 2023 Results
Go to Top